世界*實(shí)驗(yàn)材料供應(yīng)商 Dianova 正式授權(quán)上海起發(fā)為其中國(guó)代理， Dianova 在一直是行業(yè)的*,一直為廣大科研客戶提供zui為的產(chǎn)品和服務(wù),上海起發(fā)一直秉承為中國(guó)科研客戶帶來(lái)的產(chǎn)品，的服務(wù)，簽約 Dianova 就是為了給廣大科研客戶帶來(lái)更加完善的產(chǎn)品和服務(wù),您的滿意將是我們zui大的收獲

 Dianova 中國(guó)代理, Dianova 上海代理， Dianova 北京代理，Dianova 廣東代理， Dianova 江蘇代理Dianova 湖北代理,Dianova 天津,Dianova 黑龍江代理,Dianova 內(nèi)蒙古代理,Dianova 吉林代理,Dianova 福建代理, Dianova 江蘇代理, Dianova 浙江代理, Dianova 四川代理,

Dianova公司為德國(guó)的病理免疫組化產(chǎn)品供應(yīng)商，具備的抗體制備工藝及嚴(yán)格的質(zhì)控系統(tǒng)，產(chǎn)品在上享有良好的聲譽(yù)。

克隆號(hào)為H09的IDH1（isocitrate dehydrogenase 1, 異檸檬酸鹽脫氫酶1）鼠單克隆抗體為Dianova公司近期推出的產(chǎn)品之一，此抗體可特異性的檢測(cè)腦組織腫瘤中IDH1基因的R132H點(diǎn)突變。IDH1基因的第132密碼子的雜合突變是II 和III級(jí)神經(jīng)膠質(zhì)瘤（根據(jù)WHO的腫瘤學(xué)分類）的頻發(fā)事件。在大約70％的星形膠質(zhì)細(xì)胞瘤和少突神經(jīng)膠質(zhì)細(xì)胞瘤可發(fā)現(xiàn)IDH1基因的R132H點(diǎn)突變。

IDH1基因R132H突變?cè)诓糠帜X腫瘤中的頻發(fā)現(xiàn)象使克隆號(hào)為H09的IDH1抗體可高靈敏性和高特異性的用于此類腫瘤的鑒別診斷中：如從原發(fā)性膠質(zhì)母細(xì)胞瘤中區(qū)分出間變性星形細(xì)胞瘤、從毛細(xì)胞型星形細(xì)胞瘤或室管膜（細(xì)胞）瘤中區(qū)分出彌漫性星形細(xì)胞瘤（WHO分類II級(jí)），也可以用于具有IDH1突變的腫瘤細(xì)胞浸潤(rùn)前沿的與反應(yīng)性神經(jīng)膠質(zhì)增多癥的區(qū)分。因此，由于其高靈敏性和高特異性，此抗體在腦部腫瘤的分類分級(jí)中以及在檢測(cè)單一或少量浸潤(rùn)腫瘤細(xì)胞時(shí)是非常有用的。

DIA-CAL-100 – Anti-mutiertes Calreticulin / CALR (Hu) aus Maus (Klon: CAL2) für Paraffingewebe – 100 µl

Art.-Nr.                    DIA-CAL-100

Spezifität                  mutated CALR

Spezies-Reaktivität         Human

Wirtsspezies                Maus

Isotyp                      IgG2a

Klon                        CAL2

Klonalität (Mono-/Polyklonal)      monoklonal

Anwendung                         Immunhistochemie (IHC)

                                  Immunhistochemie (Paraffingewebe)

Konjugation                        unkonjugiert

Verdünnung                         Histo-/Zytochemie 1:20 – 1:40

Format                             Lyophilisat

                                   gereinigter Antikörper (aus Kulturüberstand)

Produktlinie / Thema               Immunhistochemie

                                   Tumormarker/-biologie

Zweckbestimmung                    nur für Forschungszwecke

Suchcode                           Calreticulin Mutation

                                    FFPE
                                    Paraffin

Hersler / Marke                 dianova

Practical Implementation:

CAL2 labels the megakaryocytes in myeloproliferative neoplasms (essential thrombocythaemia (ET) and primary myelofibrosis (PMF)) with CALR mutation and enables to distinguish ET and PMF with CALR mutation from polycythemia vera (PV), from CALR mutation negative ET and PMF and from reactive bone marrow.

Why is CAL2 able to detect all known types of CALR mutations?

All types of CALR mutation result in a novel C-terminus. This harbors a common epitope expressed in all kinds of CALR mutations. The CAL2 antibody is directed against this common epitope. Therefore, it can be concluded that the CAL2 antibody is able to detect all CALR mutations.

CAL2 IHC of four PMF cases:

A and C: Selective staining of mutated CALR protein in megakaryocytes of two PMF cases, respectively in prefibrotic phase and in fibrotic phase, in which Sanger sequencing detected a CALR mutation.

B and D: Absent CAL2 staining in two PMF cases, respectively in prefibrotic and in fibrotic phase, both without molecularly detected mutated CALR. The fibrotic stroma remains unstained (C and D).

A

B

C

D

References

1. Bonifacio M et al. CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations. BLOOD 128: 3122, 2016
2. Nomani L et al. CAL2 Immunohisto-chemical Staining Accuray Identifies CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol. 146(4): 431-438, 2016.
3. Andrici J et al. Mutation specific immuno-histochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology 48(4): 319-324, 2016
4. Stein, H et al. A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin embedded bone marrow sections. Leukemia 2015, accepted for publication.
5. Nangalia J et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med 369(25): 2391-2405, 2013.
6. Klampfl T et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med 369(25): 2379-2390, 2013.

部分產(chǎn)品信息如下：

我們公司zui大優(yōu)勢(shì)是強(qiáng)大的采購(gòu)，

1：基本什么都能進(jìn)口，血清，抗體，耗材，還有部分限制進(jìn)口的，

2：貨品全，現(xiàn)經(jīng)營(yíng)過(guò)700多個(gè)品牌，基本所有生物試劑耗材都可以進(jìn)口，特別是冷偏的產(chǎn)品那就更有優(yōu)勢(shì)，

3：提供加急服務(wù)，一般1-2周到貨，超過(guò)時(shí)限加急費(fèi)全免

4：價(jià)格公道，絕大部分價(jià)格有優(yōu)勢(shì)，當(dāng)然不能保證100%產(chǎn)品都是,因?yàn)橐馕吨鴽](méi)有服務(wù).

5：良好的信譽(yù)，大部分客戶我們提供貨到付款服務(wù)，客戶包括清華，北大 交大 復(fù)旦，中山等100多所大學(xué)，ROCHE，阿斯利康，國(guó)藥 ，fisher等500多家公司

6：我們還是Santa,Advanced Biotechnologies Inc, Dianova,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. Dako,Inc, GePromegaridege,Dianova  Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Dianova , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國(guó)外公司授權(quán)代理。
7：我們還是invitrogen,qiagen,Midland BioProducts Corporationam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知名*批發(fā)，歡迎合作。